CD274 and neoplasm: The authors demonstrated increased levels of PD-L1 expression, increased amounts of circulating CD8+ and CD4+ T cells, and increased inflammation at tumor sites distant from the injected lesions (even in patients with low levels of tumor infiltrating lymphocytes [TIL]) [41].